-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Atezolizumab monotherapy has good efficacy in the first-line treatment of patients with EGFR/ALK wild-type squamous or non-squamous locally advanced or metastatic non-small cell lung cancer (NSCLC) whose tumors express highly programmed Death Ligand 1 (PD-L1)
In a study published today in the top medical journal Nature Medicine to prospectively assess blood TMB (bTMB), researchers conducted the B-F1RST trial (NCT02848651), an open-label 2 Phase III clinical trial evaluating bTMB as a predictive biomarker for first-line atezolizumab monotherapy in locally advanced or metastatic stage IIIB-IVB non-small cell lung cancer (n=152)
The study's co-primary endpoints were investigator-assessed objective response rate (ORR) for RECIST version 1.
The investigator-assessed PFS of bTMB≥16 group and bTMB<16 group was not statistically significant
Thus, the development of bTMB as a predictive, stand-alone immunotherapy biomarker or in combination with other biomarkers requires further research and optimized analysis
The development of bTMB as a predictive, stand-alone immunotherapy biomarker or in combination with other biomarkers requires further research and optimized analysis
Original source:
Original source:Edward S.
Edward S.
Kim, et al.
Blood-based tumor mutational burden as a biomarker for atezolizumab in non-small cell lung cancer: the phase 2 B-F1RST trial .
Nature Medicine.
2022.
https:// articles/s41591-022-01754-x.
Blood-based tumor mutational burden as a biomarker for atezolizumab in non-small cell lung cancer: the phase 2 B-F1RST trialLeave
a comment here